Mobile App Intervention on Reducing the Myeloproliferative Neoplasm Symptom Burden: Pilot Feasibility and Acceptability Study.
mobile application
mobile phone
myeloproliferative neoplasm
self-management
symptom burden
wellness
Journal
JMIR formative research
ISSN: 2561-326X
Titre abrégé: JMIR Form Res
Pays: Canada
ID NLM: 101726394
Informations de publication
Date de publication:
31 Mar 2022
31 Mar 2022
Historique:
received:
14
09
2021
accepted:
12
01
2022
revised:
21
12
2021
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life. This study aims to determine the feasibility of a 12-week global wellness mobile app intervention in decreasing MPN symptom burden. The University of Arizona Andrew Weil Center for Integrative Medicine's global wellness mobile app, My Wellness Coach (MWC), guides patients to improve their health and well-being through facilitating behavior changes. Of the 30 patients enrolled in a 12-week intervention, 16 (53%) were retained through the final assessment. Feasibility was assessed by the ease of recruitment, participant adherence, and mobile app acceptability. App acceptability was measured using the user version of the Mobile Application Rating Scale. MPN symptom burden was measured at baseline and 12 weeks after the intervention. Recruitment was efficient, with the participant goal reached within a 60-day period, suggestive of a demand for such an intervention. Adherence was less than the target within study design (75%), although similar to mobile device app use in other studies (53%). The app was deemed acceptable based on the mean user version of the Mobile Application Rating Scale 3-star rating by participants. Finally, there were statistically significant improvements in several MPN symptoms, quality of life, and total score on the Myeloproliferative Neoplasm Symptom Assessment Form surveys. Our 12-week intervention with the MWC app was feasible and was associated with a decrease in MPN symptom burden. Further investigation of the MWC app for use as a self-management strategy to reduce the symptom burden in patients with MPN is warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Myeloproliferative neoplasms (MPNs) are a group of myeloid malignancies associated with significant symptom burden. Despite pharmacological advances in therapies, inadequate management of MPN symptoms results in reduced quality of life.
OBJECTIVE
OBJECTIVE
This study aims to determine the feasibility of a 12-week global wellness mobile app intervention in decreasing MPN symptom burden. The University of Arizona Andrew Weil Center for Integrative Medicine's global wellness mobile app, My Wellness Coach (MWC), guides patients to improve their health and well-being through facilitating behavior changes.
METHODS
METHODS
Of the 30 patients enrolled in a 12-week intervention, 16 (53%) were retained through the final assessment. Feasibility was assessed by the ease of recruitment, participant adherence, and mobile app acceptability. App acceptability was measured using the user version of the Mobile Application Rating Scale. MPN symptom burden was measured at baseline and 12 weeks after the intervention.
RESULTS
RESULTS
Recruitment was efficient, with the participant goal reached within a 60-day period, suggestive of a demand for such an intervention. Adherence was less than the target within study design (75%), although similar to mobile device app use in other studies (53%). The app was deemed acceptable based on the mean user version of the Mobile Application Rating Scale 3-star rating by participants. Finally, there were statistically significant improvements in several MPN symptoms, quality of life, and total score on the Myeloproliferative Neoplasm Symptom Assessment Form surveys.
CONCLUSIONS
CONCLUSIONS
Our 12-week intervention with the MWC app was feasible and was associated with a decrease in MPN symptom burden. Further investigation of the MWC app for use as a self-management strategy to reduce the symptom burden in patients with MPN is warranted.
Identifiants
pubmed: 35357315
pii: v6i3e33581
doi: 10.2196/33581
pmc: PMC9015738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e33581Informations de copyright
©Hninyee Win, Samantha Russell, Betsy C Wertheim, Victoria Maizes, Robert Crocker, Audrey J Brooks, Ruben Mesa, Jennifer Huberty, Holly Geyer, Ryan Eckert, Ashley Larsen, Krisstina Gowin. Originally published in JMIR Formative Research (https://formative.jmir.org), 31.03.2022.
Références
J Food Prot. 2013 May;76(5):867-70
pubmed: 23643130
JMIR Mhealth Uhealth. 2015 Nov 04;3(4):e101
pubmed: 26537656
BMC Complement Altern Med. 2019 Jun 7;19(1):121
pubmed: 31174535
JMIR Form Res. 2019 Apr 29;3(2):e12662
pubmed: 31033443
Blood. 2021 Mar 4;137(9):1145-1153
pubmed: 33237986
Nurs Res. 2017 May/Jun;66(3):246-251
pubmed: 28448375
J Med Internet Res. 2015 Jun 03;17(6):e136
pubmed: 26041682
Cancer. 2007 Jan 1;109(1):68-76
pubmed: 17123268
Pediatr Blood Cancer. 2017 Oct;64(10):
pubmed: 28423223
Gynecol Oncol. 2015 Jun;137(3):508-15
pubmed: 25681782
PLoS One. 2018 Jul 26;13(7):e0201166
pubmed: 30048546
Mediators Inflamm. 2015;2015:284706
pubmed: 26538823
Am J Lifestyle Med. 2017 Sep 13;13(6):615-618
pubmed: 31662729
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
F1000Res. 2019 Aug 9;8:
pubmed: 31448091
Support Care Cancer. 2018 Nov;26(11):3721-3728
pubmed: 29732483
J Med Internet Res. 2018 Oct 29;20(10):e273
pubmed: 30578205
Chest. 2013 May;143(5 Suppl):e420S-e436S
pubmed: 23649450
J Clin Oncol. 2018 Sep 1;36(25):2647-2655
pubmed: 29889605
JCO Clin Cancer Inform. 2018 Dec;2:1-11
pubmed: 30652617
JMIR Mhealth Uhealth. 2019 Aug 29;7(8):e12983
pubmed: 31469081
JMIR Mhealth Uhealth. 2019 Mar 18;7(3):e10921
pubmed: 30882352
Eur Endocrinol. 2019 Apr;15(1):18-24
pubmed: 31244906
Blood Rev. 2020 Jul;42:100706
pubmed: 32517877
J Clin Nurs. 2022 Apr;31(7-8):909-921
pubmed: 34231273
Ann Med. 2014 Nov;46(7):439-55
pubmed: 25012964
BMC Med Inform Decis Mak. 2019 Oct 21;19(1):196
pubmed: 31638964
Leuk Lymphoma. 2014 Mar;55(3):595-600
pubmed: 23768070
Curr Hematol Malig Rep. 2019 Jun;14(3):164-170
pubmed: 31093888
Cancer Manag Res. 2019 Jul 22;11:6663-6680
pubmed: 31413628
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
South Med J. 2015 May;108(5):290-7
pubmed: 25972217
Health Educ Q. 1995 May;22(2):190-200
pubmed: 7622387
JMIR Mhealth Uhealth. 2019 Feb 04;7(2):e11094
pubmed: 30714943
Rural Remote Health. 2019 Jan;19(1):4895
pubmed: 30673294
Cancer Med. 2020 Dec;9(24):9445-9453
pubmed: 33140580
JMIR Mhealth Uhealth. 2019 Aug 27;7(8):e13245
pubmed: 31456578
Aust Occup Ther J. 2015 Dec;62(6):420-7
pubmed: 26286379
Acta Oncol. 2019 Sep;58(9):1307-1314
pubmed: 31284797
Curr Hematol Malig Rep. 2017 Oct;12(5):389-396
pubmed: 28948496
JMIR Mhealth Uhealth. 2015 Mar 11;3(1):e27
pubmed: 25760773
J Clin Oncol. 2012 Nov 20;30(33):4098-103
pubmed: 23071245
PLoS One. 2012;7(8):e43134
pubmed: 22905215
Transl Behav Med. 2022 Jun 05;:
pubmed: 35661225